First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations

CONCLUSION: CHT-IO is superior to CHT, and IO alone also effective for METΔ14ex NSCLC, especially in the presence of TP53 mutations and independent of PD-L1 expression, but never-smokers are at higher risk of primary …